A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how doctors determine the best treatment for cancer patients—by enhancing how tumor samples are analyzed in the lab.
The findings, published in Nature Medicine, showed that AI can accurately predict genetic mutations from routine pathology slides—potentially reducing the need for rapid genetic testing in certain cases.
The paper is titled “Enhancing Clinical Genomics in Lung Adenocarcinoma with Real-World Deployment of a Fine-Tuned Computational Pathology Foundation Model.”